Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design
Clin Colorectal Cancer
.
2020 Sep;19(3):e71-e72.
doi: 10.1016/j.clcc.2020.02.011.
Epub 2020 Mar 6.
Authors
Deniz Can Guven
1
,
Gurkan Guner
2
,
Burak Yasin Aktas
2
,
Oktay Halit Aktepe
2
,
Hakan Taban
2
,
Zafer Arik
2
Affiliations
1
Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey. Electronic address: denizcguven@hotmail.com.
2
Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.
PMID:
32224043
DOI:
10.1016/j.clcc.2020.02.011
No abstract available
Publication types
Letter
Comment
MeSH terms
Chemotherapy, Adjuvant
Colonic Neoplasms* / drug therapy
Humans
Leucovorin / therapeutic use
Oxaliplatin / therapeutic use
Tegafur*
Substances
Oxaliplatin
Tegafur
Leucovorin